Intravenous Nesiritide vs Nitroglycerin for Treatment of Decompensated Congestive Heart Failure
Top Cited Papers
Open Access
- 27 March 2002
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 287 (12), 1531-1540
- https://doi.org/10.1001/jama.287.12.1531
Abstract
Context Decompensated congestive heart failure (CHF) is the leading hospital discharge diagnosis in patients older than 65 years. Objective To compare the efficacy and safety of intravenous nesiritide, intravenous nitroglycerin, and placebo. Design, Setting, and Patients Randomized, double-blind trial of 489 inpatients with dyspnea at rest from decompensated CHF, including 246 who received pulmonary artery catheterization, that was conducted at 55 community and academic hospitals between October 1999 and July 2000. Interventions Intravenous nesiritide (n = 204), intravenous nitroglycerin (n = 143), or placebo (n = 142) added to standard medications for 3 hours, followed by nesiritide (n = 278) or nitroglycerin (n = 216) added to standard medication for 24 hours. Main Outcome Measures Change in pulmonary capillary wedge pressure (PCWP) among catheterized patients and patient self-evaluation of dyspnea at 3 hours after initiation of study drug among all patients. Secondary outcomes included comparisons of hemodynamic and clinical effects between nesiritide and nitroglycerin at 24 hours. Results At 3 hours, the mean (SD) decrease in PCWP from baseline was –5.8 (6.5) mm Hg for nesiritide (vs placebo, P<.001; vs nitroglycerin, P = .03), –3.8 (5.3) mm Hg for nitroglycerin (vs placebo, P = .09), and –2 (4.2) mm Hg for placebo. At 3 hours, nesiritide resulted in improvement in dyspnea compared with placebo (P = .03), but there was no significant difference in dyspnea or global clinical status with nesiritide compared with nitroglycerin. At 24 hours, the reduction in PCWP was greater in the nesiritide group (−8.2 mm Hg) than the nitroglycerin group (−6.3 mm Hg), but patients reported no significant differences in dyspnea and only modest improvement in global clinical status. Conclusion When added to standard care in patients hospitalized with acutely decompensated CHF, nesiritide improves hemodynamic function and some self-reported symptoms more effectively than intravenous nitroglycerin or placebo.This publication has 12 references indexed in Scilit:
- Subcutaneous administration of brain natriuretic peptide in experimental heart failureJournal of the American College of Cardiology, 2000
- Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart FailureThe New England Journal of Medicine, 2000
- Effects of Brain Natriuretic Peptide on Exercise Hemodynamics and Neurohormones in Isolated Diastolic Heart FailureCirculation, 1996
- Guidelines for the Evaluation and Management of Heart FailureJournal of the American College of Cardiology, 1995
- Heart failure: Evaluation and care of patients with left ventricular systolic dysfunctionJournal of Cardiac Failure, 1995
- Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).Circulation, 1993
- Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart FailureThe New England Journal of Medicine, 1993
- Effect of Oral Milrinone on Mortality in Severe Chronic Heart FailureThe New England Journal of Medicine, 1991
- Sudden unexpected death in patients with congestive heart failure: a second frontier.Circulation, 1985
- Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failureThe American Journal of Cardiology, 1984